Molbio Diagnostics Aims for ₹940 Crore via IPO: A High-Risk Investment?

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) to raise a total of ₹940 crore. The company plans to secure ₹200 crore through a fresh issue of shares aimed at enhancing its capital expenditures. Simultaneously, it intends to generate ₹740 crore by reducing the promoter stake via an offer for sale. This strategic move will see the promoter group's stake reduce from 46.6% to 43% post-IPO.

Global Reach and Revenue Streams

Founded in 2000, Molbio Diagnostics has established itself with six manufacturing facilities in India, serving customers across more than 90 countries. Its clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Notably, the company derives over half of its revenue from its top clients, indicating a concentration risk that investors should consider.

The company's flagship product, the 'Truenat' platform, is a portable diagnostics system designed for resource-limited settings. It offers rapid and accurate test results for over 30 diseases, including tuberculosis, which accounts for 70% of the revenue from its diagnostic test kits. This innovation has been integral in gaining substantial market traction.

Financial Performance and Market Position

Molbio has demonstrated impressive financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit rose by 40.2% to ₹164.1 crore, while the operating profit before interest, tax, depreciation, and amortization (Ebitda) grew by 33.2% to ₹328.2 crore. The company achieved an Ebitda margin of 22.6% in FY26, up from 22% in FY24.

Considering the company’s financial performance and the post-IPO equity, Molbio Diagnostics is seeking a price-earnings (P/E) multiple of up to 57. While it lacks directly comparable listed peers in India, other companies in the healthcare diagnostics and medical device sectors, such as Poly Medicure and Dr. Lal PathLabs, trade at P/E multiples ranging from 54 to 81.

Investor Considerations

Given Molbio's robust growth trajectory and its strategic global presence, the IPO presents an intriguing opportunity for investors with a high-risk tolerance. However, the concentration of revenue from a limited number of clients and the competitive landscape of the diagnostics sector present potential challenges. Investors should weigh these factors alongside the company's innovative offerings and financial health when considering participation in the IPO.